ArticleeLife2021
Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys.
Article in eLife, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 99 citations in OpenAlex.
- An ultrafast SARS-CoV-2 virus enrichment and extraction method compatible with multiple modalities for RNA detection.Analytica chimica acta · 2021Trial
- Resolving parameter uncertainty in SIR models through population-level serological surveillance: A synthetic study.Infectious Disease Modelling · 2026Article
- Using forensic autopsy data to estimate the age-specific infection fatality risk of COVID-19.Epidemiology and infection · 2026Article
- The Mathematics of Serocatalytic Models With Applications to Public Health Data.Statistics in medicine · 2025Article
- A repeated cross-sectional analysis of SARS-CoV-2 seroprevalence in Manila, the Philippines after implementation of the national COVID-19 vaccination program.Tropical medicine and health · 2025Article
- Serodynamics: A primer and synthetic review of methods for epidemiological inference using serological data.Epidemics · 2024Review
- Molecular epidemiology and population immunity of SARS-CoV-2 in Guangdong (2022-2023) following a pivotal shift in the pandemic.Nature communications · 2024Article
- Phylogenetic inference of inter-population transmission rates for infectious diseases.Briefings in bioinformatics · 2024Article
- Correcting for Antibody Waning in Cumulative Incidence Estimation From Sequential Serosurveys.American journal of epidemiology · 2024Article
- Article
- Article
- Serological screening in a large-scale municipal survey in Cascais, Portugal, during the first waves of the COVID-19 pandemic: lessons for future pandemic preparedness efforts.Frontiers in public health · 2024Article
- Development of hybrid immunity during a period of high incidence of Omicron infections.International journal of epidemiology · 2023Article
- A simulation-based method to inform serosurvey design for estimating the force of infection using existing blood samples.PLoS computational biology · 2023Article
- Estimating contact network properties by integrating multiple data sources associated with infectious diseases.Statistics in medicine · 2023Article
- serosim: An R package for simulating serological data arising from vaccination, epidemiological and antibody kinetics processes.PLoS computational biology · 2023Article
- Seroprevalence of SARS-CoV-2 specific Immunoglobin G antibodies in rural population of Western Maharashtra, India.Journal of global health · 2023Article
- Article
- SARS-CoV-2 Serosurveys: How Antigen, Isotype and Threshold Choices Affect the Outcome.The Journal of infectious diseases · 2023Article
- SARS-CoV-2 and omicron variant detection with a high selectivity, sensitivity, and low-cost silicon bio-nanosensor.Nano select : open access · 2022Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Establishing how many people have been infected by SARS-CoV-2 remains an urgent priority for controlling the COVID-19 pandemic. Serological tests that identify past infection can be used to estimate cumulative incidence, but the relative accuracy and robustness of various sampling strategies have been unclear. We developed a flexible framework that integrates uncertainty from test characteristics, sample size, and heterogeneity in seroprevalence across subpopulations to compare estimates from sampling schemes. Using the same framework and making the assumption that seropositivity indicates immune protection, we propagated estimates and uncertainty through dynamical models to assess uncertainty in the epidemiological parameters needed to evaluate public health interventions and found that sampling schemes informed by demographics and contact networks outperform uniform sampling. The framework can be adapted to optimize serosurvey design given test characteristics and capacity, population demography, sampling strategy, and modeling approach, and can be tailored to support decision-making around introducing or removing interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.